Skip to main content
. Author manuscript; available in PMC: 2016 Jul 14.
Published in final edited form as: Expert Opin Drug Metab Toxicol. 2015 Jul 14;11(10):1599–1617. doi: 10.1517/17425255.2015.1068757

Figure 2.

Figure 2

Clinical Pharmacogenetics Implementation Consortium (CPIC) algorithm for suggested clinical actions based on CYP2C19 genotype when considering clopidogrel treatment for ACS/PCI patients. ACS: acute coronary syndromes; PCI: percutaneous coronary intervention; UM: ultrarapid metabolizer; EM: extensive metabolizer; IM: intermediate metabolizer; PM: poor metabolizer. 1 Other possible CYP2C19 genotypes with rare loss-of-function alleles exist beyond those illustrated (see [66]). 2 Note that prasugrel and ticagrelor are only recommended when not contraindicated clinically. Reprinted from [66] by permission of John Wiley and Sons © 2013 American Society for Clinical Pharmacology and Therapeutics.